医科学専攻

Clinical Cell Therapy細胞治療

  • 眼疾患治療法開発
  • カプセルDDS
  • 網膜色素疾患
  • ウノプロストン

STAFF

Professor

  • Nakazawa, ToruProfessor. 中澤 徹 教授 (兼任)

CONTACT

TEL:+81-22-717-7294
E-MAIL:celltherapylab*gmail.com
(「*」を「@」に変換してください)

OUTLINE

Senses consist of a variety of inputs mediated by the cerebral nerve, spinal cord and internal communication network; and it has been well known that that there are sensory inputs other than the commonly used "five senses".
Eye input is believed to account for a considerably large proportion of these senses. In addition, it is believed that the eyes have also had a great influence on diversification of living organisms.

There are various microstructures to maintain the functions of the eyes. These microstructures undergo physiological deterioration due to aging and other causes. It would be impossible to maintain and improve the quality of life without keeping the normal eye function in super aging society.
There are still a number of refractory ophthalmic diseases without treatment methods, especially retinal diseases. Our laboratory is dealing with research on such ophthalmic diseases, especially development of effective treatment methods. In addition to treatment by cell transplantation and gene therapy, we are especially concentrating on our sustained drug-releasing device that enables local release of medications in the eyes in recent years. This device developed by collaborative research with the Graduate School of Engineering is characterized by its extensible property, which allows sustained release of any drug. Therefore, it can be utilized for a variety of diseases, and we are also carrying out joint research with researchers in other fields.

感覚は脳神経・脊髄・内蔵連絡網を介するさまざまな入力からなり、通常よく使われる五感以上の感覚入力があることはよく知られています。
この中でも眼からの入力は非常に大きい割合を占めると言われており、また、眼は生物の多様化にも大きい影響を与えてきたと考えられています。
眼の機能を維持するためにさまざまな微細構造が存在しますが、加齢などの生理的現象でも精密構造に破綻が生じてきます。超高齢化社会を迎えて、眼の正常な機能なしに生活の質の維持・向上はありえません。
まだまだ難治性で治療法のない眼疾患、特に網膜疾患がたくさん存在しますが、我々の研究室はこの眼の研究、特に有効な治療法の開発を検討しています。
細胞移植や遺伝子治療以外にも、特に最近は我々が開発したデバイスによる眼局所での薬剤徐放に力を注いでいます。このデバイスは工学研究科との共同研究で作製したものですが、どのような薬剤も徐放できる拡張性に富んだもので、さまざまな病態に利用でき、他領域の研究者との共同研究も行っています。

  • Birthday party of Prof. Abe
    阿部教授の誕生会

  • Showing Sample DDS on OPEN CAMPUS
    オープンキャンパスでDDS作製の見本

  • LABO Meeting
    研究室ミーティング

  • Introduction of our LABO
    分野紹介ポスター

ARTICLE

Hoshi A, et al. “Effect of sustained insulin releasing device made of poly (ethyleneglycol) dimethacrylates on retinal function in streptozotocin-induced diabetic rats” Journal of Materials Science: Materials in Medicine, 31, 52, 2020. PMID: 32462459 DOI: 10.1007 / s10856-020-06392-8
URL:https://pubmed.ncbi.nlm.nih.gov/32462459/

Nagai N, et al. “Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats” International Journal of Pharmaceutics, 567, 118458, 2019.
PMID: 31247277 DOI: 10.1016/j.ijpharm.2019.118458
URL:https://pubmed.ncbi.nlm.nih.gov/31247277/

Nagai N, et al. “A drug refillable device for transscleral sustained drug delivery to the retina” European Journal of Pharmaceutics and Biopharmaceutics, 136, 184-191, 2019.
PMID: 30690065 DOI: 10.1016/j.ejpb.2019.01.024
URL:https://pubmed.ncbi.nlm.nih.gov/30690065/

Nagai N, et al. “Pharmacokinetic and Safety Evaluation of a Transscleral Sustained Unoprostone Release Device in Monkey Eyes” Investigative Ophthalmology & Visual Science, 59(2), 644-652, 2018.
PMID: 29392308 DOI: 10.1167/iovs.17-22429
URL:https://pubmed.ncbi.nlm.nih.gov/29392308/

Kaji H, et al. “Drug delivery devices for retinal diseases” Advanced Drug Delivery Reviews, 128, 148-157, 2018.
PMID: 28690136 DOI: 10.1016/j.addr.2017.07.002
URL:https://pubmed.ncbi.nlm.nih.gov/28690136/

一覧へ戻る
ページトップへ戻る